🟥 Member Webinar : Hemophilia Alliance Hosts – A webinar from Genentech – Reinforcing 10+ years of clinical trial experience with a subcutaneous prophylaxis treatment

All members have the option of attending our various HTC-centric events which include:

Loading Events

« All Events

  • This event has passed.

🟥 Member Webinar : Hemophilia Alliance Hosts – A webinar from Genentech – Reinforcing 10+ years of clinical trial experience with a subcutaneous prophylaxis treatment

May 7, 2024 @ 2:00 pm - 3:00 pm

Date: Tuesday, May 7, 2024
Time: 2:00pm – 3:00pm ET

Genentech Logo
Click here to register

TITLE:
Reinforcing 10+ years of clinical trial experience with a subcutaneous prophylaxis treatment, including the latest data in infants

WEBINAR OBJECTIVE:
Dr. Mike Silvey will share his perspective on managing patients with hemophilia A using a subcutaneous prophylactic treatment. The presentation will include the pivotal efficacy and safety data that is the foundation of the ongoing clinical trial program in patients with and without FVIII inhibitors, including an overview of real-world experience. Dr. Silvey will share updates from the latest trial in infants and previously untreated patients. The webinar will feature brain teasers, and showcase social media that’s engaging the hemophilia community and polls. Q&A session will follow the program.

SPEAKER:
Michael Silvey, DO
Michael Silvey, DO
HTC Director – Children’s Mercy HTC, Kansas City, MO.
Associate Professor of Pediatrics – University of Missouri-Kansas City School of Medicine.

SPEAKER’S BIO:
Michael Silvey, DO, is an Associate Professor of Pediatrics at the University of Missouri-Kansas City School of Medicine and the Associate Director of the Kansas City Regional Hemophilia Treatment Center at Children’s Mercy Hospital in Kansas City, Missouri. He received his medical degree from The Chicago College of Osteopathic Medicine. He completed his general pediatrics residency at the University of Texas Health Science Center-San Antonio and his pediatric hematology/oncology fellowship at Children’s Mercy Hospital in Kansas City, Missouri. His primary clinical and research interests are hemophilia, inherited platelet function disorders, and the coagulation system in patients with congenital heart disease as well as patients need ECMO. Dr. Silvey serves as a primary investigator for several research studies involving both bleeding and clotting disorders. In addition to enjoying taking care of pediatric bleeding disorder patients, he also likes to spend lots of time with his wife and two children and getting out on the golf course.

Details

Date:
May 7, 2024
Time:
2:00 pm - 3:00 pm
Event Categories:
,
Website:
https://attendee.gotowebinar.com/register/8747195978613954903